Pharmacokinetic profiling and therapeutic efficacy of alpha-emitter labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

Programmed cell Death Ligand 1 (PD-L1) is part of an immune checkpoint system that is essential for preventing autoimmunity. Tumor cells have developed the ability to co-opt these immune checkpoints to suppress anti-tumor immunity. PD-L1 is expressed on tumor cells, tumor associated macrophages (TAMs) and other cells within the microenvironment of the tumor. Immunotherapy using anti-PD-L1 antibody has shown promising anti-tumor effect against a number of cancers including breast cancer, and is currently used in several clinical trials. Furthermore, studies have shown that anti-PD-L1 targeted immunotherapy synergizes with radiation therapy. The aim of this study was to investigate if the therapeutic efficacy of anti-PD-L1 targeted immunotherapy is enhanced when combined with the alpha-particle emitting radiotherapeutic nuclide Actinium-225(225Ac) in a murine immunocompetent metastatic breast cancer model.

NEDROW Jessie;  JOSEFSSON Anders;  PARK Sunju;  BAECK Tom;  HOBBS Robert F.;  BRAYTON Cory;  BRUCHERTSEIFER Frank;  MORGENSTERN Alfred;  SGOUROS G.; 

2017-08-01

European Commission - Joint Research Centre

JRC106141

http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/,    https://publications.jrc.ec.europa.eu/repository/handle/JRC106141,